| 摘要 |
The invention relates to the use of binding partners for 5-HT5-receptors in the treatment of neuropathological and in particular neurodegenerative and/or neuropsychiatric disturbances which can occur notably in cases of cerebral ischaemia, cerebral stroke, epilepsy and attacks in general, chronic schizophrenia, other psychotic illnesses, dementia, notably Alzheimer's disease, demyelination diseases, notably multiple sclerosis, and brain tumors. The invention also relates to methods, especially screening methods, for identifying and characterizing such binding partners.
|
